Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1.

Leukemia·2010
Same author

Purity and recovery of the CD34+ cell fraction, obtained by the CEPRATE selection system from PBSC collections, can be augmented by meticulous washing steps.

Cytotherapy·2009
Same author

Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98).

Leukemia & lymphoma·2009
Same author

DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function.

Oncogene·2008
Same author

The hDMP1 tumor suppressor is a new WT1 target in myeloid leukemias.

Leukemia·2007
Same author

Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.

Leukemia·2006

Related Experiment Video

Updated: May 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Retinoids. Structure-function relationship in normal and leukemic hematopoiesis in vitro.

A Tobler, M I Dawson, H P Koeffler

    The Journal of Clinical Investigation
    |July 1, 1986
    PubMed
    Summary

    Retinoids modulate human myeloid cell growth and differentiation. Specific structural changes enhance retinoid activity, inhibiting leukemia cell proliferation while stimulating normal myeloid colony formation.

    More Related Videos

    Modeling Chemotherapy Resistant Leukemia In Vitro
    08:41

    Modeling Chemotherapy Resistant Leukemia In Vitro

    Published on: February 9, 2016

    A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
    08:00

    A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

    Published on: October 14, 2016

    Related Experiment Videos

    Last Updated: May 12, 2026

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 19, 2013

    Modeling Chemotherapy Resistant Leukemia In Vitro
    08:41

    Modeling Chemotherapy Resistant Leukemia In Vitro

    Published on: February 9, 2016

    A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
    08:00

    A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

    Published on: October 14, 2016

    Area of Science:

    • Hematology
    • Molecular Biology
    • Cell Biology

    Background:

    • Retinoids are crucial signaling molecules in cellular processes.
    • Understanding retinoid structure-activity relationships is key for therapeutic development.
    • Hematopoietic cell proliferation and differentiation are complex processes influenced by external factors.

    Purpose of the Study:

    • To identify key structural features of retinoids that modulate normal and leukemic human myeloid cell proliferation and differentiation.
    • To elucidate the mechanism by which retinoids influence hematopoietic cell proliferation.
    • To investigate the differential effects of retinoids on leukemic versus normal myeloid cells.

    Main Methods:

    • In vitro studies using human myeloid cell lines (HL-60, KG-1) and normal myeloid progenitor cells.
    • Synthesis and testing of various retinoid analogs with modified structures.
    • Assays for clonal growth inhibition, differentiation induction, and colony-forming cell stimulation.

    Main Results:

    • Retinoids with specific structural modifications (e.g., altered terminal carboxyl group, substituted ring systems) exhibited significantly altered activity compared to all-trans-retinoic acid.
    • Five potent retinoids strongly inhibited leukemic cell growth (HL-60, KG-1) and markedly stimulated normal myeloid colony formation (granulocyte-macrophage colony-forming cells [GM-CFC]).
    • Retinoids inhibited leukemic proliferation without inducing differentiation and appeared to modulate normal hematopoiesis by interacting with progenitor cells or enhancing sensitivity to colony-stimulating factors (CSF).

    Conclusions:

    • Common structural requirements are essential for retinoid modulation of both normal and leukemic hematopoiesis.
    • Retinoids demonstrate potential for selective inhibition of leukemic cell proliferation.
    • The mechanism of retinoid action on normal hematopoiesis involves interactions with progenitor cells or CSF signaling pathways.